×
About 15,345,785 results

Early Local Therapy Did Not Extend Survival in Patients With Newly Diagnosed Metastatic Breast Cancer
https://ascopost.com/news/june-2020/early-local-therapy-did-not-extend-survival-in-patients-with-newly-diagnosed-metastatic-breast-cancer/

Jun 1st, 2020 - Women who present at diagnosis with advanced breast cancer have faced an unanswered question: will local therapy, consisting of surgery and radiation to the tumor in the breast, prolong survival compared to the traditional treatment of systemic treatment alone?

Eric Jonasch, MD, on a Novel Therapy for Von Hippel-Lindau Disease–Associated RCC
https://ascopost.com/videos/asco20-virtual-scientific-program/eric-jonasch-on-a-novel-therapy-for-von-hippel-lindau-disease-associated-rcc/

Jun 1st, 2020 - Eric Jonasch, MD, of The University of Texas MD Anderson Cancer Center, discusses phase II study findings on the oral HIF-2α inhibitor known as MK-6482, which showed efficacy and tolerability in patients with Von Hippel-Lindau (VHL)–associated clear cell renal cell carcinoma as well as responses in other VHL-related lesions (Abstract 5003).

Howard A. Burris III, MD, FACP, FASCO, on Highlights of the ASCO20 Virtual Scientific Program
https://ascopost.com/videos/asco20-virtual-scientific-program/howard-burris-on-highlights-of-the-asco20-virtual-scientific-program/

Jun 1st, 2020 - Howard A. Burris III, MD, FACP, FASCO, talks about some of the reports of research developments he is looking forward to and how future conferences could incorporate virtual presentations.

Cynthia X. Ma, MD, PhD, on Breast Cancer: Neoadjuvant Endocrine Treatment for ER-Positive, HER2-Negative Disease
https://ascopost.com/videos/asco20-virtual-scientific-program/cynthia-ma-on-neoadjuvant-endocrine-treatment-for-er-positive-her2-negative-breast-cancer/

Jun 1st, 2020 - Cynthia X. Ma, MD, PhD, of Washington University, discusses results from the ALTERNATE trial, which showed neither fulvestrant nor fulvestrant plus anastrozole significantly improved endocrine-sensitive disease rate compared with anastrozole alone in postmenopausal patients with locally advanced estrogen receptor–positive, HER2-negative breast cancer (Abstract 504).

Meletios A. Dimopoulos, MD, on Multiple Myeloma: Selinexor, Bortezomib, and Dexamethasone for Previously Treated Patients
https://ascopost.com/videos/asco20-virtual-scientific-program/meletios-dimopoulos-on-selinexor-bortezomib-and-dexamethasone-for-previously-treated-multiple-myeloma/

Jun 1st, 2020 - Meletios A. Dimopoulos, MD, of the University of Athens, discusses phase III results from the BOSTON trial, which showed that once-weekly selinexor, bortezomib, and dexamethasone significantly improved progression-free survival and overall response rates compared with twice-weekly bortezomib and dexamethasone in patients previously treated for multiple myeloma (Abstract 8501).

Seema A. Khan, MD, MPH, on Metastatic Breast Cancer: Systemic vs Locoregional Therapies
https://ascopost.com/videos/asco20-virtual-scientific-program/seema-khan-on-systemic-vs-locoregional-therapies-for-metastatic-breast-cancer/

Jun 1st, 2020 - Seema A. Khan, MD, MPH, of the Lynn Sage Comprehensive Breast Center, discusses phase III trial results showing that in newly diagnosed metastatic stage IV breast cancer, locoregional treatment of the primary tumor did not offer a greater survival benefit than systemic therapy (Abstract LBA2).

Tingyan Shi, MD, PhD, on Ovarian Cancer: Secondary Cytoreductive Surgery for Recurrent Disease
https://ascopost.com/videos/asco20-virtual-scientific-program/tingyan-shi-on-secondary-cytoreductive-surgery-for-recurrent-ovarian-cancer/

Jun 1st, 2020 - Tingyan Shi, MD, PhD, of Zhongshan Hospital, Fudan University, discusses study results that showed secondary cytoreductive surgery in selected patients extended progression-free survival and might contribute to long-term survival (Abstract 6001).

IMvigor010 Misses DFS End Point in Muscle-Invasive Urothelial Carcinoma
https://www.onclive.com/conference-coverage/asco-2020/imvigor010-misses-primary-endpoint-in-in-miuc

May 31st, 2020 - The phase 3 IMvigor010 trial comparing adjuvant atezolizumab (Tecentriq) with observation in patients with muscle-invasive urothelial carcinoma (MIUC) failed to meet its primary endpoint of disease-free survival (DFS), according to primary analysis data presented at the 2020 ASCO Virtual Scientific Program.

Longer Follow-Up for Cemiplimab Confirms Superior Efficacy Over Other Regimens for CSCC
https://www.onclive.com/conference-coverage/asco-2020/longer-followup-for-cemiplimab-confirms-superior-efficacy-over-other-regimens-for-cscc

May 31st, 2020 - In the phase 2 trial EMPOWER-CSCC-1 (NCT02760498), up to 3 years of follow-up showed continued response rates, and a clinically meaningful survival and duration of response (DOR) for cemiplimab-rwlc (Libtayo) in patients with advanced cutaneous squamous cell carcinoma (CSCC).

Final ANANOVA2 Survival Data Support Niraparib Plus Bevacizumab in Recurrent Ovarian Cancer
https://www.targetedonc.com/view/final-ananova2-survival-data-support-niraparib-plus-bevacizumab-in-recurrent-ovarian-cancer

May 31st, 2020 - Mansoor Raza Mirza, MD, chief oncologist in the Department of Oncology at Rigshopitalet–Copenhagen University Hospital in Denmark and medical director of the Nordic Society of Gynaecological Oncology, discusses the final survival data from the randomized phase 2 NSGO-AVANOVA2/ENGOT-OV24 study, which evaluated the combination or niraparib (Zejula) plus bevacizumab (Avastin) versus niraparib alon...

Avelumab maintenance extends OS in advanced urothelial carcinoma
https://www.healio.com/hematology-oncology/genitourinary-cancer/news/online/{55a121e4-45ae-45ee-a061-27ba8bc78ad8}/avelumab-maintenance-extends-os-in-advanced-urothelial-carcinoma

May 31st, 2020 - Avelumab switch maintenance prolonged OS among patients with advanced urothelial carcinoma whose disease did not progress after first-line chemotherapy, according to study results presented during the ASCO20 Virtual Scientific Program.

Children with Down syndrome, ALL at higher risk for poor outcomes
https://www.healio.com/hematology-oncology/leukemia/news/online/{4b3c1cc4-4e4a-462e-b738-7ee6b1d20fd3}/children-with-down-syndrome-all-at-higher-risk-for-poor-outcomes

May 31st, 2020 - Children with Down syndrome and acute lymphoblastic leukemia continue to experience poorer outcomes than children with ALL who do not have Down syndrome, according to study results presented during the ASCO20 Virtual Scientific Program.

Axitinib prolongs PFS in metastatic adenoid cystic carcinoma
https://www.healio.com/hematology-oncology/head-neck-cancer/news/online/{40a4c150-78fc-4a61-ae96-5a8b84f9c6ee}/axitinib-prolongs-pfs-in-metastatic-adenoid-cystic-carcinoma

May 31st, 2020 - Axitinib significantly extended PFS among patients with recurred or metastatic adenoid cystic carcinoma, according to results of a randomized phase 2 study presented during the ASCO20 Virtual Scientific Program.

BCMA-targeted CAR-T shows ‘outstanding responses’ in advanced multiple myeloma
https://www.healio.com/hematology-oncology/myeloma/news/online/{bc81f18d-afd1-42ae-89ae-185ee74b50be}/bcma-targeted-car-t-shows-outstanding-responses-in-advanced-multiple-myeloma

May 31st, 2020 - Idecabtagene vicleucel induced responses in nearly three-quarters of patients with relapsed or refractory multiple myeloma, according to initial results of the phase 2 KarMMa trial presented during the ASCO20 Virtual Scientific Program.

CAR-T continues to show durable responses in indolent non-Hodgkin lymphoma
https://www.healio.com/hematology-oncology/lymphoma/news/online/{b5b2d115-7000-4df9-8743-26711c3bbde1}/car-t-continues-to-show-durable-responses-in-indolent-non-hodgkin-lymphoma

May 31st, 2020 - Axicabtagene ciloleucel induced a 93% response rate among patients with relapsed or refractory indolent non-Hodgkin lymphoma, according to interim results of the phase 2 ZUMA-5 trial presented during the ASCO20 Virtual Scientific Program.

Progressing malignancy linked to higher mortality among patients with cancer and COVID-19
https://www.healio.com/hematology-oncology/practice-management/news/online/{a24c9adf-558c-4ccb-ba95-8c5a2168dcbe}/progressing-malignancy-linked-to-higher-mortality-among-patients-with-cancer-and-covid-19

May 31st, 2020 - Progressing cancer appeared independently associated with increased risk for death among a cohort of patients with malignancies and COVID-19, according to study results presented during the ASCO20 Virtual Scientific Program.

First-line doxorubicin plus trabectedin effective, safe for metastatic leiomyosarcoma
https://www.healio.com/hematology-oncology/sarcoma/news/online/{28102d3c-c28b-4f98-950f-daa7db22f27d}/first-line-doxorubicin-plus-trabectedin-effective-safe-for-metastatic-leiomyosarcoma

May 31st, 2020 - Doxorubicin in combination with trabectedin appeared to be an effective and safe first-line therapy for metastatic leiomyosarcoma, according to results of the phase 2 LMS-02 study presented during the ASCO20 Virtual Scientific Program.

Longer-term imatinib treatment extends OS among patients with GIST
https://www.healio.com/hematology-oncology/sarcoma/news/online/{e2646bcc-d52d-4050-898d-1d3154b179b4}/longer-term-imatinib-treatment-extends-os-among-patients-with-gist

May 31st, 2020 - An extended course of imatinib increased OS among patients with gastrointestinal stromal tumors, or GIST, according to long-term study results presented during the ASCO20 Virtual Scientific Program.

Add-On Selinexor Boosts PFS in Pretreated Myeloma
https://www.medpagetoday.com/meetingcoverage/asco/86782

May 31st, 2020 - share to facebook share to twitter share to linkedin email article Including the XPO1 inhibitor selinexor (Xpovio) in a weekly bortezomib (Velcade) regimen improved oncologic outcomes and reduced rates of neuropathy in relapsed or refractory multiple myeloma, the phase III BOSTON trial showed.

CAR T-Cell Therapy Impresses in Indolent NHL
https://www.medpagetoday.com/meetingcoverage/asco/86783

May 31st, 2020 - Almost 100% of patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) responded to treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel, Yescarta), data from an ongoing study showed.